Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8369)	5/15/2003 1:21:20 PM
From: scaram(o)uche	Respond to of 52153

cocktails: 1. molecules interact. one can't assume that you're putting inert stuff into an inert environment. easier than it sounds. 2. regardless FDA, there are manufacturing and quality control demands on each component. margins drop, and reliable supply of "product" is dependent on the weakest link.

To: Biomaven who wrote (8369)	5/18/2003 11:48:13 AM
From: Icebrg	Respond to of 52153

Combination trials of investigational drugs. Another combination (which is perhaps a little closer to the "mainstream" than the anti-CTLA-4 plus cancer vaccine) that is now used in clinical trials is Genentech's Avastin and Tarceva. Targeting EGFr and VEGF at the same time. ClinicalTrials.gov lists four such trials. 1. Recruiting Erlotinib and Bevacizumab in Treating Women With Stage IV Breast Cancer Conditions: stage IV breast cancer; recurrent breast cancer; Male Breast Cancer 2. Not yet recruiting Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Conditions: stage IV squamous cell carcinoma of the hypopharynx; stage IV squamous cell carcinoma of the larynx; 3. Recruiting Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer Condition: Colorectal Cancer 4. Recruiting Trial of Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer in Previously Treated Patients Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell It appears as if the attitude at FDA is becoming more relaxed toward this type of combinations. Which makes a lot of sense with cancer. Erik